Current therapeutic options for extensive alopecia areata (AA) often lead to disappointing results.
Objective:
To study the efficacy and safety of adalimumab in patients with severe AA.
Methods:
This was a prospective, open-label, single-center, pilot study. Three subjects of the planned 10 were enrolled and received two weekly subcutaneous (SC) loading doses of adalimumab 80 mg followed by 40 mg SC every week for 6 months. Patients were evaluated for efficacy and safety on a monthly basis.
Results:
Enrolment in this trial was stopped following publication of studies showing no improvement in patients with AA treated with tumor necrosis factor α antagonists. One patient had a favorable response to adalimumab, whereas the two other patients had no benefit from the therapy. Adalimumab was well tolerated by patients with AA.
Conclusion:
Adalimumab was well tolerated in patients with AA but did not induce clinically significant hair regrowth.
Get full access to this article
View all access options for this article.
References
1.
SafaviK.Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol1992;128:702, doi:10.1001/archderm.1992.01680150136027.
2.
AlkhalifahA, AlsantaliA, WangE. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol2010;62:62-177; quiz 89–90, doi:10.1016/j.jaad.2009.10.032.
3.
SafaviKH, MullerSA, SumanVJ. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc1995;70:70-628, doi:10.4065/70.7.628.
4.
LuW, ShapiroJ, YuM. Alopecia areata: pathogenesis and potential for therapy. Expert Rev Mol Med2006;8(14):1-19.
5.
SinclairRD.Alopecia areata. In: SinclairRBC, DawberR, editors. Handbook of diseases of the hair and scalp. London: Blackwell Science; 1999. p. 75-84.
6.
HarriesMJ, SunJ, PausR, KingLE. Management of alopecia areata. BMJ2010;341:c3671, doi:10.1136/bmj.c3671.
7.
AlkhalifahA, AlsantaliA, WangE. Alopecia areata update: part II. Treatment. J Am Acad Dermatol2010;62:62-191; quiz 3–4.
PhilpottMP, SandersDA, BowenJ, KealeyT.Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata. Br J Dermatol1996;135:135-942, doi:10.1046/j.1365-2133.1996.d01-1099.x.
10.
BolducC, HobbsL, LuiH, editors. Efficacy of narrow-band UVB in the treatment of alopecia areata. Presented at the Canadian Dermatology Association 70th annual conference;2000; Montreal, QC.
11.
OlsenE, HordinskyM, McDonald-HullS. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol1999;40(2 Pt 1):242–6, doi:10.1016/S0190-9622(99)70195-7.
12.
HeffernanMP, HurleyMY, MartinKS. Alefacept for alopecia areata. Arch Dermatol2005;141:141-1513, doi:10.1001/archderm.141.12.1513.
13.
BuiK, PolisettyS, GilchristH. Successful treatment of alopecia universalis with alefacept: a case report and review of the literature. Cutis2008;81:81-431.
14.
KaelinU, HassanAS, BraathenLR, YawalkarN.Treatment of alopecia areata partim universalis with efalizumab. J Am Acad Dermatol2006;55:55-529, doi:10.1016/j.jaad.2006.05.062.
15.
KoldeG, MeffertH, RoweE.Successful treatment of alopecia areata with efalizumab. J Eur Acad Dermatol Venereol2008;22:22-1519, doi:10.1111/j.1468-3083.2008.02665.x.
16.
SmithJR, AkinRS, WellsMJ.Alopecia areata treated with efalizumab: a case with significant hair re-growth after long-term therapy. J Drugs Dermatol2009;8:8-758.
17.
PriceVH, HordinskyMK, OlsenEA. Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol2008;58:58-395, doi:10.1016/j.jaad.2007.10.645.
18.
TostiA, PazzagliaM, StaraceM. Alopecia areata during treatment with biologic agents. Arch Dermatol2006;142:142-1653, doi:10.1001/archderm.142.12.1653.
19.
StroberBE, MenonK, McMichaelA. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. Arch Dermatol2009;145:145-1262, doi:10.1001/archdermatol.2009.264.
20.
StroberBE, SiuK, AlexisAF. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol2005;52:52-1082, doi:10.1016/j.jaad.2005.03.039.
21.
FerranM, CalvetJ, AlmirallM. Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-alpha blocker agents. J Eur Acad Dermatol Venereol2011;25:25-479, doi:10.1111/j.1468-3083.2010.03770.x.
22.
Garcia BartelsN, LeeHH, WormM. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol2006;142:142-1654, doi:10.1001/archderm.142.12.1654.
23.
PelivaniN, HassanAS, BraathenLR. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology2008;216:216-320, doi:10.1159/000113945.
24.
ChavesY, DuarteG, Ben-SaidB. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab). Dermatology2008;217:380, doi:10.1159/000162180.
25.
KirshenC, KanigsbergN.Alopecia areata following adalimumab. J Cutan Med Surg2009;13:13-48.
26.
KatoulisAC, AlevizouA, BoziE. Biologic agents and alopecia areata. Dermatology2009;218:218-184, doi:10.1159/000174826.
27.
EttefaghL, NedorostS, MirmiraniP.Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol2004;140:1012, doi:10.1001/archderm.140.8.1012-a.
28.
FabreC, DereureO.Worsening alopecia areata and de novo occurrence of multiple halo nevi in a patient receiving infliximab. Dermatology2008;216:216-185, doi:10.1159/000111523.
29.
NakagomiD, HaradaK, YagasakiA. Psoriasiform eruption associated with alopecia areata during infliximab therapy. Clin Exp Dermatol2009;34:34-923, doi:10.1111/j.1365-2230.2008.03127.x.
30.
PostenW, SwanJ.Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol2005;141:141-759, doi:10.1001/archderm.141.6.759.
31.
PanY, RaoNA.Alopecia areata during etanercept therapy. Ocul Immunol Inflamm2009;17:17-127, doi:10.1080/09273940802596559.
32.
AbramovitsW, LosornioM.Failure of two TNF-alpha blockers to influence the course of alopecia areata. Skinmed2006;5:5-177, doi:10.1111/j.1540-9740.2006.05443.x.
